期刊文献+

干扰素治疗乙型肝炎病例对照探讨 被引量:1

下载PDF
导出
摘要 目的:探讨抗病毒药物干扰素治疗乙型肝炎的临床疗效。方法:2009年1月~2011年3月,选择我院乙肝患者共82例,随机分为两组,对照组40例应用拉米夫定治疗,观察组42例给予干扰素治疗。治疗后随访观察两组临床症状改善和不良反应发生情况。结果:治疗后两组间比较,HBV-DNA转阴率上,两组差异有统计学意义(P<0.05)。结论:干扰素治疗乙肝患者,其临床疗效确切,且能增强患者免疫功能,为有效而且理想抗病毒治疗乙肝药物。
作者 李敏
出处 《内蒙古中医药》 2011年第16期97-98,共2页 Inner Mongolia Journal of Traditional Chinese Medicine
  • 相关文献

参考文献4

二级参考文献9

  • 1拉米夫定临床应用专家组 ,万谟彬.2004年拉米夫定临床应用专家共识[J].中华肝脏病杂志,2004,12(7):425-428. 被引量:257
  • 2沈龙,彭晋.阿德福韦酯与拉米夫定抗乙型肝炎病毒作用比较[J].临床荟萃,2005,20(4):235-237. 被引量:21
  • 3Lau DT,Everhart J,Kleiner DE,et al.Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa.Gastroenterology,1997,113:1660-1667.
  • 4van Zonneveld M,Honkoop P,Hansen BE,et al.Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.Hepatology,2004,39:804-810.
  • 5Liaw YF,Sung J J,Chow WC,et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease.N Engl J Med,2004,351:1521-1531.
  • 6Yao FY,Terrault NA,Freise C,et al.Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation:a comparative study using a matched,untreated cohort.Hepatology,2001,34:411-416.
  • 7Keeffe EB,Dieterich DT,Han SH,et al.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States:an update.Clin Gastroenterol Hepatol,2006,4:936-962.
  • 8中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量:14013
  • 9茅益民,曾民德.抗乙型病毒性肝炎新药——阿德福韦酯[J].中华肝脏病杂志,2004,12(1):61-63. 被引量:266

共引文献67

同被引文献17

  • 1Ferir G, Kaptein S, Neyts J, et al.Antiviral treatment o~ehronic hepatitis B virus infections : the past, the present and the future[J].Rev Med Virol, 2008, 18(1) : 19-34.
  • 2Liaw Y F, Chu C M.Hepatitis B virus infection[J].Lancet, 2009, 373(9663) : 582-592.
  • 3Manesis E K, Hadziyannis S J.Interferon alpha treatment and retreatment of hepatitis B eantigen-negative chronic hepatitis[J].Gastroenterology, 2001, 121(1) : 101-109.
  • 4Guidotti L G, Morris A, Mendea I-I, et al.[nterferon-regulated pathways that control hepatitis B birus replication in transgenic mice[J]. J Virol, 2002, 76(6) : 2617-2621.
  • 5Wieland S F, Vega R G, Muller R, et al.Serching for interferon- induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes[J]. J Virol, 2003, 77(2) : 1227-1236.
  • 6Fried M W, Piratrisuth T, Lau G K, et al.HBeAg and Hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HbeAg-positive chronic Hepatities B[J].Hepatology, 2008, 47(2) : 428- 434.
  • 7Lampertico P, Vigano M, Manenti E, et al.Low resistance to adefovir combined with lamivudine : a 3-year study of 145 lamivudine-resistant hepatitis B patients[J].Gastroenterologu, 2007, 133(5) : 1445-1451.
  • 8Heathcote J, George J, Gordon S, et al.Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg positive chronic hepatitis B : week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103)[J].J Hepatol, 2008, 48f2) : 32.
  • 9Marcellin P, Jacobson I, Habersetzer F, et al.Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg negative chronic hepatitis B : week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102)[J]. J Hepatol, 2008, 48(2) : 26.
  • 10金文年,陈延涛.保肝降酶汤治疗乙型肝炎100例疗效观察[J].吉林中医药,2008,28(7):498-498. 被引量:5

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部